Effect of Prednisone Dosing on Mineralocorticoid-Related Side Effects With Abiraterone in Prostate Cancer
JCO Oncology Practice · 2025-05 · 21 (5) · 637-646
DOI: 10.1200/op-24-00472 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2025-05. Verfasst von Maksym Goryachok und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado School of Medicine, Aurora, CO. Hauptthemen laut MEDLINE: Prednisone, Prostatic Neoplasms, Androstenes, Mineralocorticoids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Abiraterone use for prostate cancer can cause mineralocorticoid excess syndrome (MES; eg, hypertension and hypokalemia). Prednisone mitigates these effects; however, the optimal dose level is unclear. This study examines MES effects from abiraterone with 5 mg of prednisone once daily versus 5 mg twice daily. METHODS Data for 1,410 abiraterone-treated patients from 2011 to 2022 were identified from a large academic/community hospital system. Three hundred and fifty-three patients were excluded for missing medication data and use of an alternative steroid; 1,057 patients remained (5 mg once daily, n = 550, 5 mg twice daily, n = 507). Prednisone dose was treated as a time-varying covariate. Hypokalemia and hypertension incidence over 24 weeks after abiraterone initiation was analyzed via Cox proportional hazard models using Common Terminology Criteria for Adverse Events (v5.0) grading via direct clinical measurements and International Classification of Diseases (ICD)-10 code outcomes. RESULTS Patients receiving 5 mg of prednisone twice daily had a statistically significant decrease in cumulative hazard for experiencing at least one MES event (hypertension and/or hypokalemia) via direct clinical measurement (hazard ratio [HR], 0.79 [CI, 0.68 to 0.91]; P = .002) and by ICD-10 code (HR, 0.65 [CI, 0.54 to 0.79]; P < .001) analysis. This finding was durable with individual end point analysis of hypertension and hypokalemia. There were no changes to BMI or hyperglycemia (>140 mg/dL) between the cohorts. CONCLUSION This retrospective analysis shows a decrease in risk for the development of at least one episode of hypertension or hypokalemia with abiraterone using 5 mg twice-daily prednisone in the study population. Assessments of metabolic impacts (BMI, hyperglycemia) did not show differences with prednisone dosing. These findings may merit consideration when determining an optimal prednisone dosing regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Colorado School of Medicine, Aurora, CO.
- Department of Biostatistics and Bioinformatics, University of Colorado School of Medicine, Aurora, CO.
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
- Division of Urology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO.
ORCID-Profile: Maksym Goryachok, Andrew Nicklawsky, Hiba Ahmad, Simon Kim, Thomas W Flaig
Förderung
- NCI NIH HHS
Zitieren
APA
Goryachok, M., Nicklawsky, A., Ahmad, H., Geiger, C., Kim, S., & Flaig, T. W. (2025). Effect of Prednisone Dosing on Mineralocorticoid-Related Side Effects With Abiraterone in Prostate Cancer. JCO Oncology Practice, 21(5), 637-646. https://doi.org/10.1200/op-24-00472
Vancouver
Goryachok M, Nicklawsky A, Ahmad H, Geiger C, Kim S, Flaig TW. Effect of Prednisone Dosing on Mineralocorticoid-Related Side Effects With Abiraterone in Prostate Cancer. JCO Oncology Practice. 2025;21(5):637-646. doi:10.1200/op-24-00472
BibTeX
@article{Goryachok2025,
author = {Goryachok, Maksym and Nicklawsky, Andrew and Ahmad, Hiba and Geiger, Christopher and Kim, Simon and Flaig, Thomas W},
title = {Effect of Prednisone Dosing on Mineralocorticoid-Related Side Effects With Abiraterone in Prostate Cancer},
journal = {JCO Oncology Practice},
year = {2025},
volume = {21},
number = {5},
pages = {637--646},
doi = {10.1200/op-24-00472}
}
EUVIMED